Login / Signup

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.

Emma J GroenMarieke E M van der NoordaaMichael SchaapveldGabe S SonkeRitse M MannMette S van RamshorstEsther H LipsMarie-Jeanne T F D Vrancken PeetersFrederieke H van DuijnhovenJelle Wesseling
Published in: Breast cancer research and treatment (2021)
As DCIS can respond to NST containing HER2-blockade, the presence of extensive DCIS in HER2-positive breast cancer before NST should not always indicate a mastectomy. The predictive factors we found could be helpful when considering breast-conserving surgery in these patients.
Keyphrases